title: [A case of corticobasal degeneration of which movemental disturbances were improved by administration of amantadine].
abstract: Corticobasal degeneration(CBD) is a neurodegenerative disorder characterised clinically by apraxia, cortical sensory loss, alien limb, dementia, oculomotor abnormalities, dysarthria, postural instability, akinesia, rigidity, and pyramidal signs. Brain imaging may demonstrate greater abnormalities contralateral to the more affected side. We reported a case of corticobasal degeneration of which praxic impairments were improved by administration of amantadine. The patient was a 63-year-old right-handed woman. She showed marked dysfunction including rigidity, limb kinetic apraxia, cortical sensory loss, ideomotor apraxia, and dressing apraxia. A brain MRI scan revealed bilateral cortical atrophy centered in the postcentral gyrus, more pronounced in the left hemisphere than the right. A SPECT scan showed a decrease in blood flow in the temporo-parieto-occipital regions, more pronounced in the left hemisphere than the right. An EEG showed a diffuse slowness. L-dopa had no effect on the symptoms of rigidity, limb kinetic apraxia, cortical sensory loss, ideomotor apraxia, and dressing apraxia. By administration of amantadine, rigidity and cortical sensory loss did not improve, but some praxic impairments, such as dressing apraxia and ideomotor apraxia, and the EEG improved. Upon withdrawal of amantadine, the improved symptoms deteriorated. Amitriptyline did not improve the deteriorated symptoms. After amantadine was re-administered, the same praxic impairments and the EEG improved again. This suggested that administration of amantadine had some effect on certain praxic impairments and the EEG.
authors.affiliation: Department of Neuropsychiatry, Ehime University School of Medicine, Shigenobu-cho, Onsen-gun, Ehime 791-0295, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yasuoka
authors.forename: M
authors.initials: M
authors.lastname: Ikeda
authors.forename: N
authors.initials: N
authors.lastname: Maki
authors.forename: K
authors.initials: K
authors.lastname: Hokoishi
authors.forename: K
authors.initials: K
authors.lastname: Komori
authors.forename: H
authors.initials: H
authors.lastname: Tanabe
mesh_terms: D000547:Amantadine / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001072:Apraxias / Q000188:drug therapy; D001480:Basal Ganglia Diseases / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D019636:Neurodegenerative Diseases / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D000547:Amantadine